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ABSTRACT  
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a racemic drug of abuse and its 
two enantiomers are known to differ in their dose-response curves. The S-enantiomer was 
shown to be eliminated at a higher rate than the R-enantiomer. The most likely explanation for 
this is a stereoselective metabolism also claimed in in vitro studies. Urinary excretion studies 
showed that the main metabolites in humans are 4-hydroxy 3-methoxymethamphetamine 
(HMMA) 4-sulfate, HMMA 4-glucuronide and 3,4-dihydroxymethamphetamine (DHMA) 3-
sulfate. For stereoselective pharmacokinetic analysis of these phase II metabolites in human 
blood plasma useful analytical methods are needed. Therefore the aim of the presented study 
was the development and validation of a stereoselective LC-MS/MS method for the 
simultaneous quantification of MDMA, 3,4-methylenedioxyamphetamine, DHMA, DHMA 3-
sulfate, HMMA, HMMA 4-glucuronide, HMMA 4-sulfate, and 4-hydroxy 3-
methoxyamphetamine in blood plasma for evaluation of the stereoselective pharmacokinetics 
in humans. Blood plasma samples were prepared by simple protein precipitation and 
afterwards all analytes were derivatized using N-(2,4-dinitro-5-fluorophenyl) L-valinamide 
resulting in the formation of diastereomers which were easily separable on standard reverse 
phase stationary phases. This simple and fast method was validated according to international 
guidelines including specificity, recovery, matrix effects, accuracy and precision, stabilities, 
and limits of quantification. The method proved to be selective, sensitive, accurate and precise 
for all tested analytes except for DHMA. The method was applied to the analysis of more than 
400 samples from a controlled study after application of MDMA. 
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Introduction 
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is an illicit drug of abuse that 
possesses in addition to its amphetamine-like stimulant effects also hallucinogenic properties, 
leading to feelings of energy, friendliness, euphoria and empathy [1-4]. After decreasing 
numbers of MDMA seizures in recent years, most likely due to its non-availability on the 
illicit drug market, the Substance Abuse and Mental Health Services Administration and the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) have reported on 
increasing MDMA consumption in the United States and Europe again since 2010 [5, 6]. 
Consumption of MDMA may lead to severe acute poisonings including symptoms such as 
tachycardia, hypertension, hyperthermia, or serotonin syndrome [1, 2]. Neurotoxic effects to 
serotonic neurons have been described, but are still controversial discussed in terms of species 
and dosing [7-9]. MDMA metabolism is suspected to be responsible for neurotoxicity 
presumably through the formation of glutathion adducts [10-16]. 
Figure 1 describes the main metabolic pathways of MDMA observed in humans. The major 
pathway includes O-demethylenation to 3,4-dihydroxymethamphetamine (DHMA), followed 
by O-methylation mainly to 4-hydroxy-3-methoxymethamphetamine (HMMA). DHMA is 
mainly further sulfated by sulfotransferases to DHMA 3-sulfate and DHMA 4-sulfate. 
HMMA can be further conjugated by UDP-glucuronyltransferases or by sulfotransferases. A 
minor pathway includes demethylation to 3,4-methylendioxyamphetamine (MDA) followed 
by demethylenation to 3,4-dihydroxyamphetamine, O-methylation to 4-hydroxy-3-
methoxyamphetamine (HMA) and conjugation [17-19]. In urine samples of recreational 
MDMA users following a controlled single dose of MDMA, DHMA 3-sulfate, HMMA 4-
sulfate and HMMA 4-glucuronide were detected as major metabolites next to unchanged 
MDMA [20].  
Chemically, MDMA is a ring-substituted phenylalkylamine derivative that possesses a chiral 
center. Different properties regarding pharmacological effects, neurotoxicity and in vivo 
kinetics for the two enantiomers R- and S-MDMA are described [1, 2, 21-24]. The S-
enantiomer is eliminated at a higher rate than the R-enantiomer [1, 2, 21-24] most likely 
explained by stereoselective metabolism as claimed in various vitro experiments [25-28]. 
In order to perform systematic pharmacokinetic studies on the stereoselectivity in vivo, 
respective analytical methods are needed. So far, the most commonly used instrumental 
technique for chiral analysis of MDMA and metabolites, is gas chromatography-mass 
spectrometry (GC-MS). Mainly derivatization with different chiral derivatization reagents is 
employed, leading to the formation of diastereomers which can be separated by achiral 
chromatography methods [25, 29-32]. All these methods require hydrolysis procedures of 
glucuronides and sulfates. However, for complete investigation of stereoselectivity in MDMA 
metabolism monitoring the intact phase II metabolites is of major importance. Methods, 
especially stereoselective ones, for phase II metabolites of MDMA are scarce in the literature. 
Shima et al published an LC-MS method for detection and quantification of HMMA sulfate 
and glucuronide in human urine [33], but only for the racemates. Schwaninger et al. aimed to 
stereoselectively determine all relevant phase II metabolites in human urine, however, three 
different methods employing GC-MS and LC-MS were necessary to analyze all metabolites 
in a stereoselective manner [34]. Recently, Nakanishi et al described a new LC-MS method 
after chiral derivatization with N-(2,4-dinitrophenyl)-D-leucinamide for stereoselective 
analysis of MDMA as well as of HMMA sulfate and HMMA glucuronide in urine, but 
unfortunately this method did not cover DHMA sulfates [35]. To the best of our knowledge 
no stereoselective methods for detection and quantification of MDMA and all relevant phase 
II metabolites in blood plasma are available at the moment. Therefore, the aim of the 
presented study was the development and validation of a stereoselective method for 
simultaneous analysis of MDMA and all relevant phase I and phase II metabolites in human 
blood plasma. This method should be used for the analysis of blood plasma samples from a 
double-blind, placebo-controlled, crossover study with 125 mg of MDMA. 
Experimental 
Chemicals and reagents 
Hydrochlorides of racemic MDA, HMA, MDMA, HMMA and DHMA and methanolic 
solutions (1 mg/mL) of MDA-d5 and MDMA-d5 were obtained from Lipomed (Arlesheim, 
Switzerland). 4-hydroxymethamphetamine (pholedrine), 3,4-dihydroxybenzylamine (DHBA) 
and the derivatization reagent N-(2,4-dinitro-5-fluorophenyl) L-valinamide (DNPV) were 
from Sigma Aldrich (Buchs, Switzerland). R/S-DHMA sulfates, R/S-HMMA 4-sulfate and 
single diastereomers of HMMA 4-glucuronides were synthesized as described in refs.[28, 36]. 
S-MDMA was a kind gift of The Department of Experimental and Clinical Pharmacology and 
Toxicology, Saarland University, Germany and had been prepared through enantioseparation 
of racemic MDMA as described in ref. [25]. Water was purified with a Millipore filtration 
unit and acetonitrile (ACN) and methanol of HPLC grade were obtained from Fluka (Buchs, 
Switzerland). All other chemicals used were from Merck (Zug, Switzerland) and of the 
highest grade available.  
 
LC-MS/MS Method Development 
Sample preparation for method development 
To 50 µL of each analyte solution (100 µM each) 100 µL of carbonate buffer (1 M, pH 9) and  
100 µL of DNPV (0.3 % in acetone) were added and the mixture was left in a heating block 
for 30 min at 50°C. Afterwards the reaction was stopped by the addition of 20 µL 1M HCl. 
Finally, 180 µL of a mixture of mobile phase A and B (1:1, v/v, see below) were added and 
aliquots of 10 µL of this solution were injected into the LC-MS/MS system. 
 
Optimization of MS parameters 
The analysis was performed using a Thermo Fischer Ultimate 3000 UHPLC (Thermo Fisher,  
San Jose, California, USA) system coupled to an ABSciex 5500 QTtrap linear ion trap (LIT) 
quadrupole mass spectrometer (ABSciex, Darmstadt/Germany). The Turbo V ion source was 
operated in positive ESI mode with the following MS conditions: gas 1, nitrogen (50 psi); gas 
2, nitrogen (60 psi); ion spray voltage, 4500; ion-source temperature, 550 °C; curtain gas, 
nitrogen (30 psi), collision gas, medium. The MS was operated in the enhanced product ion 
(EPI) scan mode using the following settings: mass range 50-1000, scan rate 10,000 Da/s, 
dynamic fill time.  
EPI scans were recorded for the expected protonated molecular ion of the potentially 
underivatized and of the one-, two-, and threefoldly derivatized analytes, respectively. Two 
runs were performed for each substance, first with collision energy (CE) set to 10 eV, second 
with a CE of 40 eV. 
 
Chromatography optimization  
Different mobile phases were tested on a Phenomenex (Aschaffenburg, Germany) Kinetex 
C18 column (100 x 2.1 mm, 2.6 µm) for the stereoselective separation of all analytes. First 
experiments were performed using gradient elution with 25 mM ammonium acetate buffer in 
water containing 0.1 % (v/v) acetic acid (A) and acetonitrile containing 0.1 % (v/v) acetic acid 
(B) at a flow rate of 0.5 mL/min. Secondly a mobile phase composition of 5 mM ammonium 
formate in water containing 0.1% (v/v) formic acid (C) and 5 mM ammonium formate in 
methanol containing 0.1 % (v/v) formic acid (D) at a flow rate of 0.4 mL/min were tested. 
Further experiments were conducted using eluent C and changing mobile phase D to ACN 
containing 0.1% (v/v) formic acid (E) or a mixture of methanol/ACN (3:1, v/v) containing 
0.1% formic acid (F).  
 
Determination of elution order of R and S enantiomers 
Elution order of R and S enantiomers of MDA, DHMA, HMMA, DHMA 3-sulfate, DHMA 4-
sulfate and HMMA 4-sulfate were evaluated using incubations of S-MDMA with human liver 
S9 fraction (HLS9) as generally described in ref. [26]. Elution order of MDMA and HMMA 
glucuronide was determined by injection of a derivatized sample of the single S-stereoisomer 
[25, 28]. For determination of the elution order of HMA, additionally racemic MDA was 
incubated with HLS9.  
 
Final Procedure for LC-MS/MS analysis 
Blood plasma samples 
Human blood samples (blank) were obtained from 10 different volunteers of the Zurich 
Institute of Forensic Medicine as lithium heparine blood. Blood plasma was obtained after 
centrifugation at 5,000g for 15 minutes and stored at -20 °C until further usage.  
 
Sample Preparation and chiral derivatization of blood plasma  
The plasma samples were prepared by simple protein precipitation. Briefly, to 200 µL plasma 
mixed with 20 µL of the internal standard (IS) mixture (MDMA-d5, MDA-d5, pholedrine, 
DHBA, 2.5 µM each) 1000 µL of acetonitrile were added; the mixture was shaken and 
centrifuged (10,000g, 5 min). An aliquot of 1000 µL was transferred into an autosampler vial, 
50 µL of formic acid were added and the mixture was evaporated to dryness under a gentle 
stream of nitrogen at 40 °C. The residue was dissolved in 100 µL of carbonate buffer (1 M, 
pH 9).  100 µL of DNPV (0.3 % in acetone) were added and the mixture was left in a heating 
block for 30 min at 50°C. Afterwards the reaction was stopped by the addition of 20 µL 1M 
HCl. Finally, 80 µL of a mixture of mobile phase A and B (1:1, v/v) were added and aliquots 
of 10 µL of this solution were injected into the LC-MS/MS system. 
 
Apparatus  
The analysis was performed using a Thermo Fischer Ultimate 3000 UHPLC system (Thermo 
Fisher,  San Jose, California, USA) coupled to an ABSciex 5500 QTtrap linear ion trap (LIT) 
quadrupole mass spectrometer (ABSciex, Darmstadt/Germany). 
The LC settings were as follows: Phenomenex (Aschaffenburg, Germany) Kinetex C18 
column (100 x 2.1 mm, 2.6 µm), gradient elution with 25 mM ammonium acetate buffer in 
water containing 0.1 % (v/v) acetic acid (A) and acetonitrile containing 0.1 % (v/v) acetic acid 
(B). The flow rate was 0.5 mL/min with the following gradient: 0-2 min 2% B, 2-25 min to 
60% B, 25-26 min hold at 60% B, 26-27 min to 100% B, 27-29 min hold at 100% B and at 
29.01 min reequilibrating to 2% B for 2 min. 
The Turbo V ion source was operated in positive ESI mode with the following MS conditions: 
gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 4500; ion-source 
temperature, 550 °C; curtain gas, nitrogen (30 psi), collision gas, medium. The MS was 
operated in the multiple reaction monitoring (MRM) mode using 3 transitions for each analyte 
except for the ISs where 1 MRM transition was applied. The MS settings for each analyte are 
given in Table 1.  
 
Data analysis 
Analyst software (1.6.2) was used for peak integration and quantification of data.  
 
Method Validation 
Preparation of calibration and quality control (QC) samples 
Separate stock solutions (1 mM) of each racemic analyte and for the single diastereomers of 
HMMA 4-glucuronide were prepared in water/acetonitrile. Working solutions (1, 10, 50, 100, 
200 mM) were prepared by dilution from each stock solution. Spiking solutions for 
calibration standards and QC samples were prepared by mixing appropriate amounts of the 
corresponding stock or working solution to obtain concentrations ten times higher than the 
corresponding blood plasma concentration. All solutions were stored in aliquots at -20°C.  
Calibration standards and QC samples (LOW, MED, HIGH) were prepared from 200 µL 
analyte-free blood plasma and 20 µL of the corresponding fortifying solution. The final 
calibration and QC concentrations are given in Table 2 for each stereoisomer.  
 
Selectivity and cross talk 
50 µL of each analyte solution and each IS (100 µM) were derivatized separately as described 
above and analyzed for interferences in the other MRM transitions.  
 
Specificity 
Ten blank blood plasma samples from different sources were analyzed for peaks interfering 
with the detection of analytes or IS. Two zero samples (blank sample + IS) were analyzed to 
check for appropriate IS purity and presence of native analytes.  
 
Recovery and matrix effects 
Recovery (RE) and matrix effect (ME) were determined at QC LOW and HIGH concentration 
using 6 different blood plasma sources according to the simplified approach described by 
Matuszewski et al [37]. 
 
Calibration model 
Replicates (n=6) at each concentration level were analyzed as described above. The regression 
lines were calculated using non-weighted, a weighted [1/X], and a weighted [1/X2] least-
squares regression models. The final choice of model was made after calculating validation 
data using these alternatives. Daily calibration curves (single measurement per level) were 
prepared with each batch of validation samples. The back-calculated concentrations of all 
calibration samples were compared to their respective nominal values and quantitative 
accuracy was required within 30% of target. 
 
Accuracy and precision 
QC samples (LOW, MED, HIGH) were analyzed according to the procedures described 
above in duplicate on each of eight days. Accuracy was calculated in terms of bias as the 
percent deviation of the mean calculated concentration at each concentration level from the 
corresponding theoretical concentration. Intra-day and inter-day precision were calculated as 
relative standard deviation (RSD) according to ref. [38]. 
 
Stability 
Processed sample and freeze-thaw stability were investigated at QC LOW and HIGH 
concentration (n=6 each) according to ref. [38]. Long-term stability experiments for phase II 
metabolites were performed after 24 months at QC LOW and HIGH concentration (n = 6, 
each), calculated via a freshly prepared calibration curve and accuracy was compared to 
nominal concentrations.   
 
Limits 
The lowest point of the calibration curve was defined as the limit of quantification (LOQ) of 
the method and fulfilled the requirement of LOQ, signal to noise ratio of 10:1 determined via 
peak heights. The limit of detection (LOD) was not systematically investigated.  
 
Proof of applicability 
Blood plasma samples from a double-blind, placebo-controlled, crossover study with 125 mg 
of MDMA administered to healthy volunteers were assayed with the described method.  
 
Results and discussion 
LC-MS/MS Method Development 
The S-enantiomer of MDMA is eliminated at a higher rate than the R-enantiomer [1, 2, 21-24] 
most likely explained by stereoselective metabolism that was observed in various in vitro 
experiments [25-28]. So far, chiral pharmacokinetic studies in blood mainly focused on 
MDMA and MDA [22, 39] and some also on DHMA and HMMA, but only after conjugate 
cleavage [24, 30]. Stereoselective differences could be seen for MDMA with preference for 
the R-enantiomer. For the metabolites, slight preferences for S-stereoisomers were observed 
but not to the same extent as for MDMA. Systematic chiral pharmacokinetic studies of all 
relevant phase I and II metabolites are still missing in the literature. Elimination studies in 
human urine following controlled administration of MDMA showed, that in fact HMMA 4-
sulfate, HMMA 4-glucuronide and DHMA 3-sulfate are the major excretion products of 
MDMA (Figure 1). So far no stereoselective methods for detection and quantification of 
MDMA and all relevant phase II metabolites in blood plasma are available. Due to their high 
polarity and therefore low volatility, analysis of phase II metabolites is mainly done by LC-
MS techniques. For chiral analysis usually chiral HPLC columns are used [40]. However, 
they are expensive, and their ability to actually separate two enantiomers mainly relies on trial 
and error. Recent publications managed to separate the stereoisomers of HMMA 4-
glucuronide using a pirkle brush chiral stationary phase. However MDMA and its other 
metabolites could not be stereoselectively separated by this method [34]. Other methods 
separated the enantiomers of MDMA, but no phase II metabolites, on cyclodextrine stationary 
phases [25]. Chiral derivatization with different chiral derivatization reagents is a commonly 
used enantioseparation technique for GC-MS analysis. However, in LC-MS analysis 
derivatization is rather uncommon. Recently, Nakanishi et al described a new LC-MS method 
after chiral derivatization with N-(2,4-dinitrophenyl)-D-leucinamide for stereoselective 
analysis of MDMA as well as HMMA 4-sulfate and HMMA 4-glucuronide, but not for 
DHMA sulfates in urine [35]. Similar to this method a new method was developed using N-
(2,4-dinitro-5-fluorophenyl) L-valinamide (DNPV). In this study DNPV was chosen as 
derivatization reagent as it was commercially available in Europe. The analogue as L- amino 
acid was prefered over the D-form as it was significantly cheaper. As shown in Figure 2, 
chemical reaction of DNPV with MDMA and its phase I and II metabolites leads to the 
formation of diastereomers that can subsequently be separated on standard reversed phase 
stationary phases.  
The analytes included in the method were chosen based on the main metabolites identified in 
urine [20] and on the measurement of five authentic MDMA blood samples checking for all 
possible metabolites. In these samples mainly MDMA, HMMA 4-sulfate, HMMA 4-
glucuronide, and DHMA 3-sulfate could be detected. Minor amounts of MDA, unconjugated 
HMMA, and DHMA 4-sulfate were present. DHMA and HMA as well as glucuronides of 
DHMA could not be detected in any of these samples. As DHMA and HMA were 
commercially available they were nevertheless included into the method.  
As the final derivatives are not available as reference material derivatization had to be 
performed in order to produce these derivatives. Standard MS tuning procedures for MRM 
transitions did not work from this chemical reaction solvent, probably due to an excess of 
derivatization reagent still present in the mixture. Therefore determination of MRM 
transitions for the final method had to be performed manually. For that purpose, methods 
were written for each analyte targeting the underivatized, onefoldly derivatized and in cases 
where multiple derivatization was theoretically possible, two- and threefold derivatives. EPI 
spectra were recorded using a CE of 10 eV and 40 eV, respectively. No differences in the 
abundances of the fragment ions were observed between the R and S stereoisomers. As 
exemplarily depicted in Figure 3 for HMMA 4-sulfate-DNPV, from these EPI spectra three 
fragment ions and a reasonable CE were chosen per analyte for the final MRM method. For 
all analytes complete derivatization was observed. As derivatized DHMA sulfates were only 
detectable as deconjugated analytes after an in-source fragmentation and loss of the sulfate 
moiety, the deconjugated analytes were used as precusor ions for the final method.  
The chosen derivatization procedure lead to the formation of diastereomers that should be 
separable on a chiral column. Using ammonium acetate (A) and ACN (B) as mobile phase, all 
analytes were nicely separated into their two stereoisomers, except for DHMA-DNPV. A 
change in mobile phase composition to ammonium formate and methanol allowed also the 
separation of DHMA-DNPV isomers, however, resulting in a coelution of MDA-DNPV and 
DHMA 3-sulfate-DNPV isomers. Also other mobile phase compositions of ammonium 
formate with ACN, or a mixture of ACN and methanol did not result in a separation of all 
analytes. As DHMA was not present in any authentic sample, A and B were finally employed 
as solvents accepting the coelution of R- and S-DHMA-DNPV. The final chromatogram of an 
extract of an QC MED sample is given in Figure 4. The elution order of the stereoisomers 
could be determined for MDMA-DNPV and HMMA 4-glucuronide-DNPV using the 
available S-stereoisomer after chiral derivatization. The elution order of all other metabolite 
diastereomers could be determined by synthesis of the corresponding metabolites by 
incubation of S-MDMA with HLS9 fractions containing cytochrome P450-, catechol-O-
methyltransferase- and sulfotransferase enzymes as principally described in ref. [18]. HMA 
could not be synthesized from S-MDMA in quantitative sufficient amounts. In order to 
determine its elution order nevertheless, racemic MDA was incubated evaluating the ratio of 
the two HMA peaks after DNPV derivatization. S-MDA was shown to be metabolized 
preferentially resulting in the larger peaks [41]. With our derivatization procedure, the R-
stereoisomers of all metabolites were identified to elute before the S-stereoisomers, except for 
MDA-DNPV, HMA-DNPV, and DHMA 4-sulfate-DNPV, where the elution order was 
reversed. Enantiomer differentiation was essential for determining MDMA’s stereoselective 
pharmacokinetics in blood plasma.  
 
Method Validation 
The described final procedure was validated according to recommendations on method 
validation in the context of quality management with forensic-toxicological investigations 
published by the GTFCh [38] and internationally accepted recommendations [42-46]. 
 
Specificity, Selectivity, and Cross Talk 
Blank blood plasma samples from 10 different sources were analyzed for chromatographic 
interferences. No interfering peaks were detected for any of the analytes in blank samples or 
after addition of the IS solution. 
Furthermore derivatized analytes were analyzed for cross talk and interferences in the MRM 
transitions of the other analytes. Again, no cross talk for any compound could be detected. 
This was one of the advantages of using derivatization in LC-MS. Usually, MDMA, MDA, 
HMMA, and HMA show very similar fragment ion and are prone to cross talk. Through one- 
and twofold derivatization, fragmentation was altered and resulted in different fragment ions.   
 
Recovery and matrix effects 
RE and ME data are listed in Table 3. All analytes could be extracted with REs over 60% with 
acceptable CVs except for the glucuronides. Most probably, the used protein precipitation 
leads also to co-precipitation of part of the glucuronides. Different extraction procedures such 
as solid phase extraction or liquid liquid extraction were considered, however due to the large 
differences in the physico-chemical properties of MDMA and its phase II metabolites, 
discarded.  
No notable MEs were observed for any of the analytes, except for HMMA 4-glucuronide-
DNPV at QC LOW and for DHMA-DNPV. However, the ME for HMMA 4-glucuronide-
DNPV was reproducible (CV < 11%) and was therefore accepted for pharmacokinetic studies. 
The sensitivity for DHMA-DNPV was altogether rather low and its detection was only 
possible for QC MED and QC HIGH. Quite a large ME could be detected for DHMA-DNPV 
in QC HIGH (390%, CV 60%) by calculation via the area only. Adjustment via DHBA-
DNPV as IS, which is generally used for quantification, lead to acceptable ME with 91% 
(19% CV) as given in Table 3.   
 
Calibration model 
Calibration curves using six concentration levels with six replicates each were constructed to 
evaluate the calibration model. The limits for the calibration curve were assessed based on 
data published by [47] determined after controlled administration of MDMA.  Calibration 
ranges for all analytes are given in Tables 2 and should allow quantification without further 
dilution.  
A weighted (1/X2) calibration model was used to account for unequal variances 
(heteroscedasticity) across the calibration range. As there were several possibilities with 
different ISs and calibration models, the final decision was made after evaluation of the 
accuracy and precision data. The final calibration model was linear, 1/X2 weighting for all 
analytes.  
 
Accuracy and precision 
QC samples (LOW, MED, and HIGH) were analyzed in duplicate on each of eight days as 
was proposed by Peters et al [48]. QC concentrations were determined from daily calibration 
curves. Calibrator concentrations were within 30% of target based on the full calibration 
curve. Accuracy, intra-day and inter-day precision were calculated as described above (Table 
3).  
Respective deuterated analogues were employed for MDA and MDMA. As for all other 
metabolites no deuterated standards were commercially available, pholedrine was 
successfully used for HMMA 4-sulfate, HMMA 4-glucuronide, DHMA 3-sulfate, DHMA 4-
sulfate, HMMA and HMA. DHMA was calculated with DHBA as IS due to its structural 
similarities.  
All analytes fulfilled the validation parameters except for DHMA-DNPV, DHMA 4-sulfate-
DNPV at QC LOW and HMMA-glucuronide-DNPV at QC LOW. As already mentioned the 
sensitivity for DHMA-DNPV was rather low, most likely due to the fact that it was 
threefoldly derivatized. It could be detected from concentrations equal or higher than 
calibrator 3 and QK MED. Even in QK MED and QK HIGH the inter-day precision was 
above the acceptance criteria of +/- 15%. However, DHMA was not present in any of the 
analyzed authentic samples. For DHMA 4-sulfate-DNPV in QC LOW the observed bias was 
slightly lower than the acceptance criteria and for HMMA 4-glucuronide-DNPV intra- and 
interday precision was slightly above the acceptance criteria of +/- 20%. No significant 
differences were observed between R- and S-stereoisomer. All together the method was 
sufficient for pharmacokinetic analysis of authentic samples after a controlled administration 
of MDMA in blood plasma.  
 
Stability 
No degradation was observed for any derivatized analyte in processed samples stored on the 
autosampler for 48 h at ambient temperature. All analytes were stable over three freeze-thaw 
cycles except for HMA, which was stable over only one cycle. Instability of HMA during 
freezing and thawing was already described by Kolbrich [49]. Therefore an immediate work-
up after thawing was recommended [49] which was performed for our samples.  
No instability of the phase II analytes after storage at -20°C for 24 months was observed with 
calculated concentration within +/- 20% of nominal concentration. Furthermore, no 
deconjugated analytes could be detected as would be assumed to be formed after degradation 
of phase II metabolites. Data on MDMA and its phase I metabolites as well as HMMA and 
HMA were previously published and no instability could be observed up to after 6 months 
[50].  
 
Limit of quantification 
The LOQs of all analytes are listed in Table 2 and were consistent with the lowest calibrator 
with less than 30% bias as compared to the target concentration. Those limits were 
comparable to those published by other authors for MDMA and MDA [23, 49] and were 
sufficient for the pharmacokinetic analysis in the context of a controlled single MDMA 
administration study.  
 
Proof of applicability  
The presented method was successfully applied to about 500 samples of a pharmacokinetic 
study for MDMA following controlled MDMA administration. The data of this study will be 
presented elsewhere. As shown in Figure 5, stereoselective differences could be seen in blood 
plasma samples after controlled MDMA administration.  
 
Conclusion 
A validated LC-MS/MS method for is presented for the simultaneous quantification of 
MDMA and its relevant phase I and phase II metabolites after chiral derivatization with 
DNPV in blood plasma.  The method fulfilled the required validation criteria for all analytes 
except for DHMA. The method was successfully applied for the pharmacokinetic study of 
possible stereoselective phase I and phase II MDMA metabolism after controlled 
administration of MDMA.  
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Legend to Figures 
Figure 1: Main metabolic pathways of MDMA  
 
Figure 2: Chiral derivatization with N-(2,4-dinitro-5-fluorophenyl) L-valinamide (DNPV) 
exemplified for HMMA 4-sulfate for onefold derivatization (A) and for HMMA for twofold 
derivatization (B) 
 
Figure 3: Evaluation and optimization of MS parameters for MRM quantification. A: EPI 
spectrum of HMMA 4-sulfate-DNPV at 10 eV collision energy (CE), B: EPI spectrum of 
HMMA 4-sulfate-DNPV at 40 eV CE. The dotted lines in the molecular formula represent the 
fragmentation pattern of the fragments depicted in the EPI spectra at 10(A)  and 40 eV (B). 
From the EPI spectra MRM transitions were optimized for quantification of HMMA 4-
sulfate-DNPV(C) 
 
Figure 4: Typical MRM chromatograms and elution order of derivatized R and S 
stereoisomers of MDMA and all monitored phase I and phase II metabolites at QC med 
concentration.  
 
Figure 5: MRM chromatogram of an authentic derivatized extract of a human blood plasma 
sample at tmax after ingestion of MDMA  
 
 
 
Tables 
Table 1: MS settings and retention times of the measured analytes sorted by elution order. Quantifiers are 
given in bold print. 
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R-HMMA 4-glucuronide DNPV 
652.0 165.0 13.7 100 10 30 12 
652.0 476.0 13.7 100 10 15 12 
652.0 137.0 13.7 100 10 30 12 
S-HMMA 4-glucuronide DNPV 
652.1 165.0 14.1 100 10 30 12 
652.1 476.0 14.1 100 10 15 12 
652.1 137.0 14.1 100 10 30 12 
R-HMMA 4-sulfate DNPV 
556.0 165.0 14.9 100 10 30 12 
556.0 137.0 14.9 100 10 30 12 
556.0 476.0 14.9 100 10 15 12 
S-HMMA 4-sulfate DNPV 
556.1 165.0 15.8 100 10 30 12 
556.1 137.0 15.8 100 10 30 12 
556.1 476.0 15.8 100 10 15 12 
S-DHMA 4-sulfate 2 DNPV 
742.0 386.0 19.2 100 10 30 12 
742.0 293.0 19.2 100 10 30 12 
742.0 328.0 19.2 100 10 30 12 
R-DHMA 4-sulfate 2 DNPV 
742.1 386.0 19.6 100 10 30 12 
742.1 293.0 19.6 100 10 30 12 
742.1 328.0 19.6 100 10 30 12 
R-DHMA 3-sulfate 2 DNPV 
742.0 386.1 19.8 100 10 30 12 
742.0 293.1 19.8 100 10 30 12 
742.0 328.1 19.8 100 10 30 12 
S-DHMA 3-sulfate 2 DNPV 
742.1 386.1 20.0 100 10 30 12 
742.1 293.1 20.0 100 10 30 12 
742.1 328.1 20.0 100 10 30 12 
R-MDMA d5 DNPV 479.0 165.0 20.4 100 10 19 12 
R-MDMA DNPV 
474.0 163.2 20.4 100 10 19 12 
474.0 104.9 20.4 100 10 67 14 
474.0 135.0 20.4 100 10 55 8 
S-MDMA d5 DNPV 479.1 165.0 20.9 100 10 19 12 
S-MDMA DNPV 
474.1 163.2 20.9 100 10 19 12 
474.1 104.9 20.9 100 10 67 14 
474.1 135.0 20.9 100 10 55 8 
S-MDA d5 DNPV 465.0 110.0 21.5 100 10 67 14 
S-MDA DNPV 
460.0 163.0 21.5 100 10 19 12 
460.0 105.0 21.5 100 10 67 14 
460.0 135.0 21.5 100 10 55 8 
R-MDA d5 DNPV 465.1 110.0 22.0 100 10 67 14 
R-MDA DNPV 
460.1 163.0 22.0 100 10 19 12 
460.1 105.0 22.0 100 10 67 14 
460.1 135.0 22.0 100 10 55 8 
R-HMMA 2 DNPV 
756.0 400.0 23.2 100 10 30 12 
756.0 293.0 23.2 100 10 30 12 
756.0 342.0 23.2 100 10 30 12 
 1-Pholedrine 2 DNPV 726.0 370.0 23.5 100 10 30 12 
S-HMMA 2 DNPV 
756.1 400.0 23.7 100 10 30 12 
756.1 293.0 23.7 100 10 30 12 
756.1 342.0 23.7 100 10 30 12 
2 Pholedrine DNPV 726.1 370.0 23.9 100 10 30 12 
1 HMA 2 DNPV 
742.0 279.0 24.1 100 10 30 12 
742.0 234.0 24.1 100 10 30 12 
742.0 400.0 24.1 100 10 30 12 
DHBA 3 DNPV 980.0 655.0 24.4 100 10 30 12 
DHMA 3 DNPV 
1022.0 293.0 24.8 100 10 30 12 
1022.0 397.0 24.8 100 10 30 12 
1022.0 621.0 24.8 100 10 30 12 
2 HMA 2 DNPV 
742.1 279.0 25.0 100 10 30 12 
742.1 234.0 25.0 100 10 30 12 
742.1 400.0 25.0 100 10 30 12 
Table 2: Blood plasma concentrations for calibrator (cal) and quality control (QC) samples used for method validation  
 
Blood plasma concentration µM (µg/L)  
Analyte Cal. 1 Cal. 2 Cal. 3 Cal. 4 Cal. 5 Cal. 6  QC low QC med QC high 
R-HMMA 4-glucuronide DNPV 0.0025 (0.93) 0.05 (18.6) 0.25 (92.8) 0.5 (185) 0.75 (278) 1.25 (464)  0.00375 (1.4) 0.375 (139) 1.0 (371) 
S-HMMA 4-glucuronide DNPV 0.0025 (0.93) 0.05 (18.6) 0.25 (92.8) 0.5 (185) 0.75 (278) 1.25 (464)  0.00375 (1.4) 0.375 (139) 1.0 (371) 
R-HMMA 4-sulfate DNPV 0.0025 (0.69) 0.05 (13.8) 0.25 (68.8) 0.5 (138) 0.75 (206) 1.0 (275)  0.00375 (1.0) 0.375 (103) 0.7 (193) 
S-HMMA 4-sulfate DNPV 0.0025 (0.69) 0.05 (13.8) 0.25 (68.8) 0.5 (138) 0.75 (206) 1.0 (275)  0.00375 (1.0) 0.375 (103) 0.7 (193) 
S-DHMA 4-sulfate 2 DNPV 0.0025 (0.65) 0.05 (13.1) 0.25 (65.3) 0.5 (131) 0.75 (196)   0.00375 (0.98) 0.375 (98.8) 0.6 (157) 
R-DHMA 4-sulfate 2 DNPV 0.0025 (0.65) 0.05 (13.1) 0.25 (65.3) 0.5 (131) 0.75 (196)   0.00375 (0.98) 0.375 (98.8) 0.6 (157) 
R-DHMA 3-sulfate 2 DNPV 0.0025 (0.65) 0.05 (13.1) 0.25 (65.3) 0.5 (131) 0.75 (196) 1.0 (261)  0.00375 (0.98) 0.375 (98.8) 0.7 (183) 
S-DHMA 3-sulfate 2 DNPV 0.0025 (0.65) 0.05 (13.1) 0.25 (65.3) 0.5 (131) 0.75 (196) 1.0 (261)  0.00375 (0.98) 0.375 (98.8) 0.7 (183) 
R-MDMA DNPV 0.0025 (0.48) 0.05 (9.6) 0.25 (48.3) 0.5 (96.5) 0.75 (145) 1.25 (241)  0.00375 (0.72) 0.375 (72.4) 1.0 (193) 
S-MDMA DNPV 0.0025 (0.48) 0.05 (9.6) 0.25 (48.3) 0.5 (96.5) 0.75 (145) 1.25 (241)  0.00375 (0.72) 0.375 (72.4) 1.0 (193) 
S-MDA DNPV 0.0025 (0.45) 0.005 (0.90) 0.025 (4.5) 0.05 (9.0) 0.125 (22.4) 0.25 (44.8)  0.00375 (0.66) 0.0375 (6.7) 0.2 (35.8) 
R-MDA DNPV 0.0025 (0.45) 0.005 (0.90) 0.025 (4.5) 0.05 (9.0) 0.125 (22.4) 0.25 (44.8)  0.00375 (0.66) 0.0375 (6.7) 0.2 (35.8) 
R-HMMA 2 DNPV 0.0025 (0.49) 0.005 (0.98) 0.025 (4.9) 0.05 (9.8) 0.125 (24.4) 0.25 (48.8)  0.00375 (0.73) 0.0375 (7.3 ) 0.2 (39.0) 
S-HMMA 2 DNPV 0.0025 (0.49) 0.005 (0.98) 0.025 (4.9) 0.05 (9.8) 0.125 (24.4) 0.25 (48.8)  0.00375 (0.73) 0.0375 (7.3 ) 0.2 (39.0) 
1 HMA 2 DNPV 0.0025 (0.45) 0.005 (0.91) 0.025 (4.5) 0.05 (9.1) 0.125 (22.6) 0.25 (45.3)  0.00375 (0.68) 0.0375 (6.8) 0.2 (36.0) 
2 HMA 2 DNPV 0.0025 (0.45) 0.005 (0.91) 0.025 (4.5) 0.05 (9.1) 0.125 (22.6) 0.25 (45.3)  0.00375 (0.68) 0.0375 (6.8) 0.2 (36.0) 
DHMA 3 DNPV 0.005 (0.91) 0.01 (1.8) 0.05 (9.1) 0.1 (18.1) 0.25 (45.3) 0.5 (90.5)  0.0075 (1.4) 0.075 (13.6) 0.4 (72.4) 
   
             
       
Table 3: Method validation data: bias, intra-day precision (RSDR), interday-precision (RSDT), recovery (RE), and matrix effects (ME)  
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R-HMMA 4-glucuronide DNPV -0.9 24.6 24.6 43.6 (20.3) 129.5 (11.0) 4.8 7.4 14.2  -2.3 11.3 12.6 42.9 (15.1) 99.9 (4.4) 
S-HMMA 4-glucuronide DNPV 9.5 29.9 27.7 48.2 (20.5) 126.3 (8.6) -1.7 9.7 13.2  2.9 11.5 12.3 42.7 (18.3) 101.0 (3.8) 
R-HMMA 4-sulfate DNPV -9.0 10.5 15.0 84.7 (9.9) 96.8 (4.3) -9.8 6.0 8.7  0.9 10.9 11.1 79.3 (4.5) 94.5 (3.4) 
S-HMMA 4-sulfate DNPV -9.6 10.7 14.6 81.9 (6.7) 97.8 (2.4) -9.5 7.3 9.1  -0.4 9.6 9.8 78.9 (4.8) 91.5 (5.5) 
S-DHMA 4-sulfate 2 DNPV -30.0 1.1 3.9 78.9 (13.3) 94.6 (11.8) -0.6 6.9 7.3  -6.0 10.9 10.8 79.3 (8.8) 84.8 (7.7) 
R-DHMA 4-sulfate 2 DNPV -31.2 1.1 2.8 63.9 (9.5) 101.9 (10.5) 0.0 7.0 7.4  -5.0 10.2 10.5 79.8 (8.5) 85.0 (5.6) 
R-DHMA 3-sulfate 2 DNPV -19.8 13.1 13.2 79.4 (15.5) 95.7 (5.7) -6.2 7.9 7.5  -1.6 10.4 10.2 83.3 (9.1) 80.7 (6.4) 
S-DHMA 3-sulfate 2 DNPV -16.8 7.3 13.5 77.8 (15.9) 93.6 (5.5) -4.5 8.0 7.6  -0.9 12.8 12.4 80.7 (8.5) 84.7 (6.2) 
R-MDMA DNPV -12.5 5.9 10.9 86.1 (6.9) 96.8 (7.9) -11.1 4.7 5.7  -9.1 7.0 7.3 84.2 (12.2) 100.9 (4.0) 
S-MDMA DNPV -9.4 10.9 13.5 88.8 (10.8) 95.8 (7.7) -11.6 5.7 6.4  -8.1 6.0 7.1 85.8 (12.0) 101.9 (3.6) 
S-MDA DNPV 10.8 7.4 12.2 83.9 (10.6) 92.2 (6.5) -5.3 6.5 7.8  -1.8 7.2 8.4 85.5 (12.3) 93.0 (8.0) 
R-MDA DNPV 8.0 8.9 13.5 86.9 (9.4) 92.9 (6.7) -4.8 5.8 7.8  -0.9 8.6 9.2 83.4 (10.7) 95.4 (5.3) 
R-HMMA 2 DNPV -4.7 5.5 5.9 88.7 (9.5) 112.0 (5.2) -9.7 4.2 5.5  -10.4 5.8 7.1 83.9 (8.0) 108.3 (5.2) 
S-HMMA 2 DNPV -9.6 7.6 8.3 90.4 (12.4) 125.1 (4.8) -7.5 4.2 5.8  -7.8 7.3 7.8 85.0 (7.5) 112.8 (3.4) 
1 HMA 2 DNPV -17.2 4.9 7.7 81.1 (8.2) 118.1 (6.6) -14.7 4.0 4.8  -9.5 6.8 8.4 80.6 (5.6) 98.0 (9.5) 
2 HMA 2 DNPV -15.0 4.7 7.9 58.7 (15.2) 99.8 (20.8) -15.5 5.1 5.3  -10.6 7.2 8.0 79.8 (7.5) 95.1 (5.9) 
DHMA 3 DNPV - - - - - 13.4 6.0 26.1  -7.8 15.2 22.9 79.9 (14.7) 90.6 (18.8)* 
 
* calculated using the ratio analyte/IS 
